Literature DB >> 19772902

Brain creatine kinase activity is increased by chronic administration of paroxetine.

Patricia M Santos1, Giselli Scaini, Gislaine T Rezin, Joana Benedet, Natália Rochi, Gabriela C Jeremias, Milena Carvalho-Silva, João Quevedo, Emilio L Streck.   

Abstract

Major depression is a serious and recurrent disorder often manifested with symptoms at the psychological, behavioral, and physiological levels. In addition, several works also suggest brain metabolism impairment as a mechanism underlying depression. Creatine kinase (CK) plays a central role in the metabolism of high-energy consuming tissues such as brain, where it functions as an effective buffering system of cellular ATP levels. Considering that CK plays an important role in brain energy homeostasis and that some antidepressants may modulate energy metabolism, we decided to investigate CK activity from rat brain after chronic administration of paroxetine (selective serotonin reuptake inhibitor), nortriptiline (tricyclic antidepressant) and venlafaxine (selective serotonin-norepinephrine reuptake inhibitor). Adult male Wistar rats received daily injections of paroxetine (10 mg/kg), nortriptiline (15 mg/kg), venlafaxine (10 mg/kg) or saline in 1.0 mL/kg volume for 15 days. Twelve hours after the last administration, the rats were killed by decapitation, the hippocampus, striatum and prefrontal cortex were immediately removed, and activity of CK was measured. Our results demonstrated that chronic administration of paroxetine increased CK activity in the prefrontal cortex, hippocampus and striatum of adult rats. On the other hand, nortriptiline and venlafaxine chronic administration did not affect CK activity in these brain areas. In order to verify whether the effect of paroxetine on CK is direct or indirect, we also measured the in vitro effect of this drug on the activity of the enzyme. We verified that paroxetine did not affect CK activity in vitro. Considering that metabolism impairment is probably involved in the pathophysiology of depressive disorders, an increase in CK activity by antidepressants may be an important mechanism of action of these drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19772902     DOI: 10.1016/j.brainresbull.2009.09.007

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  11 in total

1.  Administration of memantine and imipramine alters mitochondrial respiratory chain and creatine kinase activities in rat brain.

Authors:  Gislaine Z Réus; Roberto B Stringari; Gislaine T Rezin; Daiane B Fraga; Juliana F Daufenbach; Giselli Scaini; Joana Benedet; Natália Rochi; Emílio L Streck; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2011-09-28       Impact factor: 3.575

2.  Sex-specific antidepressant effects of dietary creatine with and without sub-acute fluoxetine in rats.

Authors:  Patricia J Allen; Kristen E D'Anci; Robin B Kanarek; Perry F Renshaw
Journal:  Pharmacol Biochem Behav       Date:  2012-03-10       Impact factor: 3.533

3.  The lumped constant of α-methyl-l-tryptophan is not influenced by drugs acting through serotonergic system.

Authors:  Nela Pivac; Mirko Diksic
Journal:  Neurochem Int       Date:  2011-03-22       Impact factor: 3.921

4.  Serum agrin and talin are increased in major depression while agrin and creatine phosphokinase are associated with chronic fatigue and fibromyalgia symptoms in depression.

Authors:  Hussein Kadhem Al-Hakeim; Ameer Abdul Razzaq Al-Issa; Michael Maes
Journal:  Metab Brain Dis       Date:  2019-11-16       Impact factor: 3.584

Review 5.  Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?

Authors:  Patricia J Allen
Journal:  Neurosci Biobehav Rev       Date:  2012-03-24       Impact factor: 8.989

6.  Treatment with tianeptine induces antidepressive-like effects and alters the neurotrophin levels, mitochondrial respiratory chain and cycle Krebs enzymes in the brain of maternally deprived adult rats.

Authors:  Franciela P Della; Helena M Abelaira; Gislaine Z Réus; Maria Augusta B dos Santos; Débora B Tomaz; Altamir R Antunes; Giselli Scaini; Meline O S Morais; Emilio L Streck; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-01-18       Impact factor: 3.584

7.  Effect of Imipramine, Paroxetine, and Lithium Carbonate on Neurobehavioral Changes of Streptozotocin in Rats: Impact on Glycogen Synthase Kinase-3 and Blood Glucose Level.

Authors:  Rania I Nadeem; Hebatalla I Ahmed; Ezz-El-Din S El-Denshary
Journal:  Neurochem Res       Date:  2015-07-28       Impact factor: 3.996

8.  Creatine transporter (CrT; Slc6a8) knockout mice as a model of human CrT deficiency.

Authors:  Matthew R Skelton; Tori L Schaefer; Devon L Graham; Ton J Degrauw; Joseph F Clark; Michael T Williams; Charles V Vorhees
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

9.  Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.

Authors:  R Kaddurah-Daouk; M B Bogdanov; W R Wikoff; H Zhu; S H Boyle; E Churchill; Z Wang; A J Rush; R R Krishnan; E Pickering; M Delnomdedieu; O Fiehn
Journal:  Transl Psychiatry       Date:  2013-01-22       Impact factor: 6.222

10.  Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation.

Authors:  C Webhofer; P Gormanns; V Tolstikov; W Zieglgänsberger; I Sillaber; F Holsboer; C W Turck
Journal:  Transl Psychiatry       Date:  2011-12-13       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.